Ran Nussbaum

Insider Reports History

Location
Santa Monica, CA
Signature
/s/ Marc Panoff, Attorney-in-Fact
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Ran Nussbaum:

Company Role Class Num Shares Value Price $ Report Date Ownership
UroGen Pharma Ltd. Director Ordinary Shares 1,485,168 $26,747,876 $18.01 21 Oct 2022 Managing member of entities affiliated with Pontifax Management III G.P. (2011) Ltd
Keros Therapeutics, Inc. Director, 10%+ Owner Common Stock 155,262 $2,241,983 $14.44 04 Jun 2025 Indirect
LB PHARMACEUTICALS INC Director Common Stock 1,411,681 12 Sep 2025 Indirect
LB PHARMACEUTICALS INC Director Stock Option (Right to Buy) 22,449 10 Sep 2025 Direct
Eloxx Pharmaceuticals, Inc. Director Stock Options (Right to Buy) 20,000 15 Jun 2022 Direct
Keros Therapeutics, Inc. Director, 10%+ Owner Stock Option (right to buy) 10,500 04 Jun 2025 Direct
LB PHARMACEUTICALS INC Director Series C Preferred Stock 0 12 Sep 2025 Indirect
UroGen Pharma Ltd. Director Stock Option (right to buy) 0 21 Oct 2022 By Pontifax Cayman III Limited Partnership
UroGen Pharma Ltd. Director Stock Option (right to buy) 0 21 Oct 2022 By Pontifax (Israel) III Limited Partnership

Insider Reports Filed by Ran Nussbaum

Symbol Company Period Transactions Value $ Form Type Role Filing Time
/report/000160980525000006-nussbaum-ran-2025-09-12 LB PHARMACEUTICALS INC 12 Sep 2025 3 +$15,000,000 4 Director 16 Sep 2025, 16:15
/report/000141588925024447-nussbaum-ran-2025-09-10 LB PHARMACEUTICALS INC 10 Sep 2025 1 $0 4 Director 12 Sep 2025, 18:25
/report/000141588925024247-nussbaum-ran-2025-09-10 LB PHARMACEUTICALS INC 10 Sep 2025 0 $0 3 Director, 10%+ Owner 11 Sep 2025, 09:19
KROS Keros Therapeutics, Inc. 04 Jun 2025 0 $0 4/A Director, 10%+ Owner 11 Jun 2025, 07:30
KROS Keros Therapeutics, Inc. 30 May 2024 1 $0 4 Director, 10%+ Owner 03 Jun 2024, 16:15
KROS Keros Therapeutics, Inc. 06 Jun 2023 1 $0 4 Director, 10%+ Owner 08 Jun 2023, 16:44
KROS Keros Therapeutics, Inc. 29 Nov 2022 6 -$0.7176 4 Director, 10%+ Owner 30 Nov 2022, 15:40
URGN UroGen Pharma Ltd. 21 Oct 2022 3 +$285,114 4/A Director 28 Feb 2023, 11:23
URGN UroGen Pharma Ltd. 16 Jun 2022 2 +$11,055 4 Director 28 Feb 2023, 11:21
/report/000110465922072179-nussbaum-ran-2022-06-15 Eloxx Pharmaceuticals, Inc. 15 Jun 2022 1 $0 4 Director 17 Jun 2022, 08:26
URGN UroGen Pharma Ltd. 08 Jun 2022 2 $0 4 Director 10 Jun 2022, 15:36
URGN UroGen Pharma Ltd. 06 Jun 2022 2 +$5,150 4/A Director 28 Feb 2023, 11:29
KROS Keros Therapeutics, Inc. 01 Jun 2022 1 $0 4 Director, 10%+ Owner 03 Jun 2022, 16:30
KROS Keros Therapeutics, Inc. 01 Jun 2021 1 $0 4 Director, 10%+ Owner 03 Jun 2021, 17:34
/report/000141588921002614-nussbaum-ran-2021-05-19 Eloxx Pharmaceuticals, Inc. 19 May 2021 1 $0 4 Director 20 May 2021, 16:10
/report/000110465921067335-nussbaum-ran-2021-05-13 Eloxx Pharmaceuticals, Inc. 13 May 2021 4 +$7,999,999 4 Director 17 May 2021, 07:02
URGN UroGen Pharma Ltd. 25 Mar 2021 2 +$5,150 4/A Director 09 Jun 2021, 13:46
URGN UroGen Pharma Ltd. 25 Mar 2021 4 +$11,055 4 Director 09 Jun 2021, 13:42
KROS Keros Therapeutics, Inc. 07 Apr 2020 0 $0 3/A Director, 10%+ Owner 30 Nov 2022, 15:36